Luteolin inhibits angiogenesis by blocking Gas6/Axl signaling pathway

XIAOBO LI1,2*, MINFENG CHEN1,2*, XUEPING LEI1,2, MAOHUA HUANG1,2, WENCAI YE1,2, RIJIA ZHANG3 and DONGMEI ZHANG1,2

1College of Pharmacy, Jinan University; 2Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, Jinan University; 3The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510632, P.R. China

Received April 15, 2017; Accepted May 26, 2017

DOI: 10.3892/ijo.2017.4041

Correspondence to: Dr Dongmei Zhang, College of Pharmacy, Jinan University, 601 Huangpu Road West, Guangzhou, Guangdong 510632, P.R. China
E-mail: dmzhang701@foxmail.com
Dr Rijia Zhang, The First Affiliated Hospital of Jinan University, 613 Huangpu Road West, Guangzhou, Guangdong 510632, P.R. China
E-mail: jerry_joan@163.com

*Contributed equally

Abbreviations: HMEC-1s, human microvascular endothelial cells; HBVPs, human brain vascular pericytes; ECs, endothelial cells; Gas6, growth arrest-specific protein 6; Axl, Axl receptor tyrosine kinase; VEGF, vascular endothelial growth factor; EGF, epidermal growth factor; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; Ang1, angiopoietin 1; Ang2, angiopoietin 2; VEGFR2, vascular endothelial growth factor receptor 2; PI3K, phosphatidylinositol 3-kinase; Akt, protein kinase B; mTOR, mammalian target of rapamycin; RTK, receptor tyrosine kinases; MMP-2, matrix metalloproteinase-2; MMP-9, matrix metalloproteinase-9; HSP90, heat shock protein 90; PM, pericyte medium; MEK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; NF-kB, nuclear factor X; JAK, janus kinase; STAT, signal transducer and activator of transcription; CAM, chick chorioallantoic membrane; MTT, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide

Key words: luteolin, angiogenesis, Gas6, Axl

Abstract. Growth arrest-specific protein 6 (Gas6) induces the activation of Axl receptor tyrosine kinase (Axl), which plays an important role in angiogenic processes, including proliferation, migration, invasion, tube formation and pericyte recruitment of endothelial cells. The inhibition of Gas6/Axl pathway has been demonstrated to be an effective anti-angiogenic therapy. Luteolin, which is a natural active flavonoid, has been reported to possess anti-angiogenic effects. However, the underlying mechanism of luteolin in anti-angiogenesis is not fully understood. Herein, we report that luteolin significantly inhibited the Gas6-induced proliferation, migration, invasion and tube formation of human microvascular endothelial cells (HMEC-1s) in vitro, and suppressed the Gas6-induced recruitment of human brain vascular pericytes (HBVPs) to the endothelial tubes. Luteolin also suppressed Gas6-induced microvessel sprouting in aortic ring assay and neovascularization in chick chorioallantoic membrane assay. The anti-angiogenic effect of luteolin may be associated with the inhibition of the Gas6/Axl pathway and its downstream phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathways. Taken together, the present study provides new evidence regarding an anti-angiogenic mechanism of luteolin, and supports the notion that the dietary intake of luteolin contributes to the treatment of pathological angiogenesis.

Introduction

Angiogenesis occurs when new vessels are generated from pre-existing vessels, this involves a complicated process, including vascular destabilization, extracellular matrix degradation, endothelial cell proliferation, migration, invasion, tube formation and the recruitment of pericytes. Multiple pro-angiogenic and anti-angiogenic factors, such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2), are involved in the regulation of angiogenesis (1,2). Physiological angiogenesis results from a fine-tuning balance between these pro-angiogenic and anti-angiogenic factors and establishes a well-organized vessel network to provide oxygen and nutrients to tissues. When the balance is disturbed, vessel growth is deregulated, resulting in physiological immature vessels, which may lead to pathological angiogenesis, including cancer, psoriasis, blindness, and arthritis (2,3). To inhibit pathological angiogenesis, several inhibitors and monoclonal antibodies targeting pro-angiogenic factors have been developed and applied in clinic. However, there are limitations to these anti-angiogenic agents, such as serious side effects and drug resistance, which attenuate their efficacy and hamper drug development (4,5).
Growth arrest-specific protein 6 (Gas6), which is a member of the vitamin K-dependent protein family, is an important pro-angiogenic factor. Gas6 has different affinities for Tyro-Axl-Mer (TAM) receptor tyrosine kinases (RTKs) and shows selectivity high affinities for Axl receptor tyrosine kinase (Axl) (6). The Gas/Axl axis is expressed in endothelial cells (ECs), pericytes, and smooth muscle cells (7-9), and has been demonstrated to participate in multiple angiogenic processes including survival, proliferation, migration, invasion and aggregation of ECs as well as pericyte adhesion by regulating its downstream signaling pathways, including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway, the mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway, the nuclear factor-kB (NF-kB) pathway and the janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway (10-13). Previously, many preclinical studies have shown that the inhibition of the Gas6/Axl pathway may contribute to reduction in angiogenesis (9). R428, which is a selective inhibitor of the Axl kinase, has been demonstrated to block Axl-dependent events, such as Akt phosphorylation, breast cancer cell invasion, and pro-inflammatory cytokine production (14). Desacetylvinblastine monohydrazide, which is a derivative of vinblastine, has also been reported to suppress angiogenesis in vitro and in vivo by suppressing the Gas6/Axl signaling pathway (15). In addition, the inhibition of Gas6/Axl pathway enhances the effects of multiple anti-angiogenic therapies in tumors (16). Altogether, these findings suggest that the Gas/Axl pathway is a therapeutic target for pathological angiogenesis.

Luteolin (3’, 4’, 5, 7-tetrahydroxy flavone) is widely distributed in vegetables and fruits and serves as a common dietary additive (17). Preclinical studies have demonstrated that luteolin has multiple pharmacological activities, such as anti-inflammation, anti-tumor, and anti-microbial activities (18). Moreover, luteolin dietary additive has been considered favorable in many pathological angiogenesis therapies (19). Previously, luteolin has been shown to inhibit tumor angiogenesis, including human lung cancer, breast cancer, and prostate tumor, however, the mechanism underlying this inhibition remains to be elucidated (20). In the present study, we reveal that luteolin suppresses Gas6-induced angiogenesis in vitro, ex vivo and in vivo by downregulating the Gas6/Axl signaling pathway. Our results show that luteolin inhibits Gas6-mediated proliferation, motility and tube formation of human microvascular endothelial cells (HMEC-1s), which are required for neovascularization, and Gas6-induced recruitment of pericytes during vessel maturation. In addition, using an aortic ring assay and a chick chorioallantoic membrane (CAM) assay, we demonstrate that luteolin suppresses Gas6-induced vascular sprouting and neovascularization.

Materials and methods

Materials. Luteolin (≥98% pure) was purchased from Sigma-Aldrich (St. Louis, MO, USA), dissolved in DMSO and stored at -20˚C. Fetal bovine serum (FBS) was obtained from Life Technology (Carlsbad, CA, USA). Pentobarbital sodium was purchased from Merck (Darmstadt, Germany). Matrigel was purchased from BD Biosciences (Franklin Lakes, NJ, USA). The antibodies against Axl, PI3K, p-PI3K7α78, Akt, p-AktThr308, mTOR, p-mTORSer2448, p70S6K, p-p70S6KThr389, heat shock protein 90 (HSP90), matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 9 (MMP-9), and donkey anti-Rabbit IgG were purchased from Cell Signaling Technology (Danvers, MA, USA). The p-Axl779 antibody and recombinant human Gas6 were obtained from R&D Systems (Minneapolis, MN, USA). The pericycle medium (PM) was obtained from ScienCell Research Laboratories (San Diego, CA, USA). The fertilized chicken eggs were purchased from South China Agricultural University (Guangzhou, China). PKH 26, PKH 67 and other reagents were purchased from Sigma-Aldrich.

Cell lines and cell culture. Human microvascular endothelial cells (HMEC-1s) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in RPMI-1640 medium (Gibco, Invitrogen Corp., Carlsbad, CA, USA) supplemented with 10% FBS. HBVPs were obtained from ScienCell Research Laboratories and cultured in PM. All cells were cultured at 37˚C under humidified atmosphere containing 5% CO2.

Animals. Adult male Sprague Dawley rats (weighing 180-220 g) were obtained from the Guangdong Medical Experimental Animal Center (Guangzhou, China). The animals were maintained in a specific pathogen-free room with free access to water and standard laboratory chow. All animal experiments were approved by the laboratory animal ethics committee of Jinan University (Guangzhou, China).

Cell viability assay. The effect of luteolin on the viability of HMEC-1s was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. HMEC-1s were seeded in 96-well plates at 1x10⁴ cells per well and cultured for 24 h. Then, the cells were treated with various concentrations of luteolin. After incubating for 24 and 48 h, the cell viability was determined using the MTT assay. The Gas6-induced HMEC-1s proliferation was measured by the MTT assay as previously described (21). HMEC-1s were seeded in 96-well plates at 1x10³ cells per well and cultured for 24 h. Adherent cells were starved with serum-free RPMI-1640 medium for 6 h, then, the cells were treated with various concentrations of luteolin. After incubating for 24 and 48 h, the cell viability was determined using the MTT assay.

Wound-healing migration assay. HMEC-1s were grown to 100% confluence in 6-well plates. The cells were starved with serum-free RPMI-1640 medium for 6 h, then, the cells were treated with various concentrations of luteolin, and Gas6 (100 ng/ml) was simultaneously added. After incubating for 24 and 48 h, the cell viability was determined using the MTT assay.

Transwell migration and Matrigel invasion assay. The in vitro migration and invasion were assessed using a Transwell assay with or without Matrigel as previously described (22). Briefly, 2x10⁴ HMEC-1s were suspended in 100 μl of the serum-free RPMI-1640 medium with or without various concentrations of luteolin (10 and 20 μM) added to the upper chamber insert, the
bottom chamber was filled with 600 µl of fresh RPMI-1640 medium supplemented with or without Gas6 (100 ng/ml). After 24-h incubation, the upper chamber was fixed with 4% paraformaldehyde for 30 min and the cells were stained with crystal violet. After 24-h incubation, the upper chamber was fixed with 4% paraformaldehyde for 30 min and the cells were stained with crystal violet. The non-migrated HMEC-1s that remained on the inner side of the upper chamber were removed with a cotton swab. The cells on the lower surface were photographed under an Olympus IX70 inverted microscope. For the cell invasion assay, the upper chamber was pre-coated with 35 µl of diluted Matrigel (Matrigel was diluted to a ratio of 3:1 with PBS) for 1 h at 37˚C, and the assay was performed according to the procedures described above. The migrated and invasive cells were quantified using Image-Pro Plus 6.0.

**Tube formation assay.** The HMEC-1s were seeded in Matrigel-coated 96-well plates at a density of 2.5x10^4 cells per well with or without the presence of the indicated concentrations of luteolin (10 and 20 µM), and Gas6 (100 ng/ml) was simultaneously added. After 8 h, capillary-like tubes were observed and photographed under an Olympus IX70 inverted microscope, and the number of tubes was calculated by Image-Pro Plus 6.0.

**Aortic ring assay.** The dorsal aortas were isolated from the Sprague-Dawley rats as previously described (15). Then the dorsal aortas were cut into 1- to 1.5-mm-long rings. Next, the rinsed aortic rings were placed in Matrigel-coated 96-well plates and sealed with an overlay of 60-65% humidity for 5 days (blunt end up). A small window approximately 1x1 cm, was carefully drilled in the eggshell on the gas chamber side to create an artificial gas chamber. Then, the shell and shell membrane were removed to expose the CAM. Next, a piece of filter membrane containing Gas6 (300 ng/ml) and the indicated concentrations of luteolin (10 and 20 µM) dissolved in 20 µl PBS, was placed in the center of the CAM. The window was sealed with transparent tape and the CAM was incubated for another 48 h. The microvessels in the CAM were observed under an Olympus SZX18 dissecting microscope, and the microvessels were quantified with Image-Pro Plus 6.0.

**Western blot analysis.** HMEC-1s were seeded in Matrigel-coated 96-well plates and incubated for 2 h to allow the capillary network to form. Then, 2x10^4 HBVPs, which were pre-treated with luteolin for 4 h and labeled with PKH 67 (λex=490 nm, λem=502 nm), were added to the capillary network and incubated for another 10 h to allow the HBVPs to adhere to the capillary network and form complicated and solid tubes. The capillary networks were observed and captured under an Olympus IX70 inverted microscope at 0, 2, and 10 h after the addition of HBVPs.

**Statistical analysis.** All experiments were performed in triplicate. The data are expressed as the mean ± SEM, and the statistical analyses were performed with GraphPad Prism 5.0.
Luteolin inhibits the Gas6-induced proliferation of HMEC-1s. First, the non-toxic concentration of luteolin in HMEC-1s was determined by the MTT assay. Our results showed that luteolin had a negligible effect on the proliferation of HMEC-1s at a dose range of 10 to 20 µM (Fig. 1A). Therefore, the concentrations of 10 and 20 µM were identified as non-toxic doses and used in the subsequent in vitro, ex vivo and in vivo experiments. Then, we examined the effect of luteolin on the Gas6-induced proliferation of HMEC-1s. We found that Gas6 significantly promoted the proliferation of HMEC-1s.
In addition, luteolin caused a concentration-dependent inhibitory effect on Gas6-induced growth of the HMEC-1s (Fig. 1B). Luteolin inhibits the Gas6-induced migration and invasion of HMEC-1s. The effect of luteolin on the Gas6-induced migration was evaluated by the wound-healing migration assay and Transwell assay. Confluent HMEC-1s were starved with serum-free RPMI-1640 medium for 6 h and scratched with pipette tips. Then, the cells were treated with or without luteolin and Gas6 (100 ng/ml). In the Gas6-treated group, the number of migrated HMEC-1s increased compared with the control group; however, the luteolin treatment suppressed the Gas6-induced migration of HMEC-1s (Fig. 2A). Similar results were observed in the migration chamber and invasion chamber assay. Gas6 facilitated the migration and invasion of HMEC-1s, and the stimulatory effect of Gas6 was attenuated by luteolin (Fig. 2B and C). Taken together, luteolin significantly suppressed the Gas6-induced motilities of HMEC-1s.

Luteolin inhibits the Gas6-induced angiogenesis ex vivo. We performed a tube formation assay and an aortic ring assay to examine the anti-angiogenic effects of luteolin ex vivo. In the tube formation assay, we found that the capillary-like tube networks in the Gas6-treated group were more solid and complicated than those in the control group. In contrast, luteolin significantly inhibited Gas6-induced tube formation. The number of tubes was significantly decreased after luteolin exposure (Fig. 3A). Next, we used a mouse aortic ring angiogenesis assay to investigate whether luteolin suppressed the Gas6-induced outgrowth of microvessels. The outgrowth of microvessels in the aortic ring assay was remarkably enhanced following Gas6 treatment. In contrast, luteolin markedly suppressed Gas6-induced microvessel sprouting (Fig. 3B). These results suggested that luteolin inhibited Gas6-induced angiogenesis ex vivo.

Luteolin inhibits the Gas6-induced pericyte recruitment to endothelial tubes. Since pericytes are crucial for the maturation of neovessels during late-stage angiogenesis and Axl is overexpressed in pericytes (26,27), we conducted a 3D co-culture of HMEC-1s and HBVPs to evaluate the effect of luteolin on pericyte recruitment to the endothelial tubes. A large number of HBVPs migrated to the endothelial tubes.
Figure 4. Luteolin suppresses Gas6-mediated HBVP recruitment to the endothelial tubes. (A) HBVPs (green) pre-treated with or without the indicated concentrations of luteolin for 4 h, were seeded after the endothelial tubes (red) formed. The recruitment of the HBVPs to the HMEC-1 tubes was observed and photographed after the addition of HBVPs for 2 and 12 h in the presence or absence of Gas6. Representative images are shown, scale bar, 50 µM. (B) Luteolin inhibits the Gas6-induced phosphorylation of Axl in HBVPs. The HBVPs were pre-treated with luteolin for 4 h and then stimulated with Gas6 for another 1 h. The quantitative analysis of western blotting was shown. Data were ratios of p-Axl/β-actin and Axl/β-actin, and were presented as mean ± SEM. **P<0.01 compared with the control group; ***P<0.001 compared with the Gas6-treated group.

Figure 5. Luteolin inhibits Gas6-induced angiogenesis in CAM. Representative images of chick chorioallantoic membrane in the CAM assay are shown. The fertilized eggs were treated with or without the indicated concentrations of luteolin in the presence or absence of Gas6 (300 ng/ml) for 48 h. The microvessels were observed and captured under an Olympus SZX18 dissecting microscope (magnification, x1.6). The data are presented as the mean ± SEM. **P<0.01 compared with the control group; ***P<0.001 compared with the Gas6-treated group.
within 2 h in the control group. Noteworthy, almost all Gas6-treated HBVPs migrated and adhered to the formed endothelial tubes. However, few HBVPs were recruited to the endothelial tubes in the luteolin-treated group. In addition, the tubes in the Gas6-treated group were more complex and solid after an additional 10-h incubation compared with those in the control group. However, only a few HBVP-supported tubes were observed after the luteolin treatment. These results suggested that luteolin inhibited Gas6-induced HBVP recruitment to the endothelial tubes (Fig. 4A). Then, the inhibitory effect of luteolin on the activation of Axl in HBVPs was examined by western blotting. Our results showed that luteolin significantly suppressed the Gas6-mediated phosphorylation of Axl in HBVPs (Fig. 4B).

Luteolin inhibits the Gas6-induced angiogenesis in CAM. We then conducted a CAM assay to examine the anti-angiogenic effect of luteolin in vivo. The CAM assay is a widely used and accessible system in angiogenesis studies (28). We found that the blood vessels in the Gas6-treated group formed a dense and spatially-oriented branching network, and the number of blood vessels in the embryonic neovascularization increased significantly compared with control group. However, in the luteolin-treated group, the number of blood vessels was significantly decreased compared with Gas6 group (Fig. 5). These results suggested that luteolin suppressed the Gas6-induced angiogenesis in vivo.

Luteolin inhibits the Gas6/Axl signaling pathway. The above mentioned results demonstrated that luteolin suppressed Gas6-induced angiogenesis in vitro, ex vivo and in vivo. Thus, we investigated whether this effect was associated with the suppression of the Gas6/Axl signaling pathway and explored its downstream molecular mechanisms. We found that luteolin significantly suppressed the Gas6-mediated phosphorylation of Axl, followed by the downregulation of Gas6/Axl mediated phosphorylation of the PI3K, Akt, mTOR and p70S6k (Fig. 6A and B). Luteolin also markedly inhibited the expression of MMP-2 and MMP-9 (Fig. 6B), which play crucial roles in various physiological processes, such as wound healing and vessel sprouting (29). In addition, luteolin also inhibited the expression of HSP90 (Fig. 6B), which has been shown to

---

Figure 6. Luteolin suppresses the Gas6/Axl signaling pathways in HMEC-1s. HMEC-1s were pre-treated with the indicated concentrations of luteolin for 4 h and then stimulated with Gas6 (100 ng/ml) for 1 h. Then, the cells were harvested, lysed with RIPA buffer and subjected to western blot analysis. The gray value was measured with ImageJ software. (A) Luteolin inhibited the activation of Axl in HMEC-1s. The quantitative analysis of western blotting is shown. Data were ratios of p-Axl/β-actin and Axl/β-actin, and were presented as the mean ± SEM. *P<0.01 compared with the control group; **P<0.05 compared with the Gas6-treated group. (B) Luteolin inhibited the Gas6-induced activation of the PI3K-Akt-mTOR pathway in HMEC-1s. Luteolin suppressed the activation of PI3K, Akt, mTOR and p70S6k and also downregulated the expression of MMP-2, MMP-9 and HSP90.
promote angiogenesis (30). These data indicated that luteolin inhibited Gas6-induced angiogenesis by inactivating the Gas6/Axl signaling pathway in HMEC-1s.

Discussion

Epidemiological and preclinical evidence indicates that the dietary intake of flavonoids, including luteolin and catchin, contributes to the treatment of multiple pathological angiogenesis involving cancer, arthritis and cataractogenesis. Previously, luteolin has been widely investigated to validate its anti-angiogenic effects, but the underlying mechanism is not fully understood (9,19,31,32). In the present study, we found that luteolin inhibited growth arrest-specific protein 6 (Gas6)-induced angiogenesis by inhibiting the Gas6/Axl signaling pathway. Noteworthy, we found that luteolin not only inhibited the Gas6-induced motilities of HMEC-1s (proliferation, migration, invasion and tubulogenesis) that are required for neovascularization but also suppressed the Gas6-induced recruitment of pericytes to well-established endothelial tubes, which is vital for the maturation of neovessels during the late-stage of angiogenesis. Our study provides new evidence regarding novel anti-angiogenic mechanism of luteolin and also contributes to the notion that the dietary intake of luteolin is beneficial for the treatment of pathological angiogenesis.

Gas6/Axl is expressed in blood vascular system containing endothelial cells (ECs), pericytes and smooth muscle cells (7-9). The Gas6/Axl pathway can promote proliferation, migration, invasion and tube formation of endothelia cells by regulating the PI3K/Akt/mTOR signaling pathway (26,33). Gas6-induced angiogenesis is associated with various pathological angiogenesis, including cancer, psoriasis, blindness and arthritis (2,34). Gas6 and its receptor play a crucial role in tumor angiogenesis, which functions in a variety of tumors including breast cancer, prostatic cancer and non-small cell lung cancer (3). Therefore, it is meaningful to develop an inhibitor that targets the Gas6-induced angiogenesis. Herein, we sought to determine whether the anti-angiogenic effect of luteolin is correlated with the Gas6/Axl signaling pathway. We demonstrated that luteolin significantly inhibited multiple processes of Gas6-induced HMEC-1s during angiogenesis. Luteolin also suppressed the Gas6-stimulated recruitment of HBVPs to the endothelial tubes, which promoted the maturation and stabilization of neovessels. In addition, luteolin suppressed the Gas6-induced newly branched blood vessels in the CAM. These results were due to the inactivation of the Gas6/Axl pathway, resulting in the downregulation of the PI3K/Akt/mTOR signaling pathway. Luteolin also reduced the expression of MMP-2, MMP-9 and HSP90, which are vital for the degradation of extracellular matrix (ECM) components (29). Taken together, our study provides new insight for further exploring the anti-angiogenic effect of luteolin and contributes to the understanding of its mechanism. Our study also indicates the potential of luteolin in the treatment of cancer, psoriasis, blindness and arthritis involvement of Gas6/Axl activation.

Previous studies have demonstrated that the Gas6/Axl is involved in chemoresistance in breast cancer and indicated that the inactivation of the Gas6/Axl pathway may contribute to the activity of chemotherapeutic drugs (35,36). Recent studies have demonstrated that the inhibition of the Gas6/Axl pathway improved the efficacy of chemotherapies in preclinical models of advanced pancreatic and ovarian cancer (37). Thus, the dietary intake of luteolin during therapy likely contributes to the decreased risk of resistance. In addition, luteolin has been shown to inhibit VEGF/VEGFR2-mediated angiogenesis (20,38), combined with our results, luteolin may achieve a synergistic anti-angiogenic efficacy which is similar to that achieved by combinational therapy with inhibitors targeting the Gas6/Axl and VEGF/VEGFR2 signaling pathways in anti-angiogenesis therapies.

Currently, angiogenic inhibitors are widely used in cancer therapy in clinic, including bevacizumab, a monocline antibody of VEGF, and the multi-targeted tyrosine kinase inhibitors, such as sunitinib, and sorafenib (39). However, it was reported that many side effects emerged after the treatments, the severely adverse reactions including nausea, vomiting, and drug resistance in the advanced stage, which lead to treatment failure (40). In addition, the drugs used for the treatment of angiogenesis, such as bevacizumab and ranibizumab, are quite expensive, thus many patients cannot afford the high treatment expense. However, luteolin is widely distributed in the vegetables and fruits (17), it can be obtained in our daily life as a nutritional additive thus preventing from pathological angiogenesis in clinic.

In conclusion, we demonstrate that luteolin significantly suppresses Gas6-induced angiogenesis in vitro, ex vivo and in vivo. This study investigated the potential of luteolin in clinic as a therapy for angiogenesis and it also provides evidence that dietary intake of luteolin may contribute to reducing the risk of pathological angiogenesis.

Acknowledgements

This study was supported by the Science and Technology Program of China (2012ZX09103101-053), the National Science Foundation of China (81573455) and Guangdong Province (S2013050014183 and 2013CZXDA006), the Program for New Century Excellent Talents in University and Pear River Scholar Funded Scheme (D.Z.) and the Project for Construction of Traditional Chinese Medicine Strong Province (20132114).

References


